The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term ...

About the author Chris Spivey is the editorial director of Pharmaceutical Technology Europe. Article details Pharmaceutical Technology Europe Volume 36, No. 2 February 2024 Pages 11–14 Citation When ...

The European Medicines Agency (EMA) has finally joined the discussion on artificial intelligence (AI) and machine learning (ML), releasing a draft reflection paper on the use of these technologies ...

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...